By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Promentis Pharmaceuticals, Inc. 

826 N. Plankinton Avenue
Suite 400
Milwaukee  Wisconsin  53203  U.S.A.
Phone: 1-212-375-2694 Fax: n/a


SEARCH JOBS

Promentis Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders. The Company’s lead compound is being developed to treat a psychiatric indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of unmet patient need. Promentis’ drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress. In addition, Promentis has obtained an exclusive license from Marquette University and the University of Wisconsin – Milwaukee Research Foundation to certain intellectual property owned by Marquette University and the University of Wisconsin – Milwaukee Research Foundation.

YEAR FOUNDED:

2007

LEADERSHIP:

Founders: David A. Baker and John Mansch

CEO: Klaus Veitinger

CMO: Thomas R. Beck


Key Statistics


Email: contact@promentispharma.com
Ownership: Private

Web Site: Promentis Pharma
Employees:
Symbol: 
 



Industry
Pharmaceutical






Company News
//-->